Esanex is a clinical-stage company with new scientific insights into the role of heat shock protein inhibitors as important anti-cancer agents.

Esanex is also investigating the potential role of heat shock protein inhibitors in other therapeutic applications

Learn More

The Opportunity

Our leading drug candidate, SNX-5422, provides durable responses in rationally-designed clinical trials

The Science

New insights into SNX-5422 provides the mechanistic rationale for select combination therapy,
including checkpoint inhibitors and other immuno-oncology agents

News and Events

SNX-5422 clinical profile supports development in multiple indications in both solid and hematologic tumors  and  advancement toward pivotal trials

Interested in a potential clinical study of rational drug combinations with SNX-5422?

Through it’s work to define the details of SNX-5422’s mode of action, Esanex has identified target mechanisms where efficacy is predicated to be driven by complementary rather than redundant mechanisms. Please contact us at info@esanexpharma.com with your specific interest.